|
Plasma cholesterol and triacylglycerol in minipigs treated with G. lucidum and lovastatin (mmol/L) |
||||||||||||||||
| Group |
TC |
TC |
TC |
TC |
TAG |
TAG |
TAG |
TAG |
VLDL |
VLDL |
LDL |
LDL |
HDL |
HDL |
LDL/HDL |
LDL/HDL |
| D1 |
D14 |
D21 |
D29 |
D1 |
D14 |
D21 |
D29 |
D14 |
D29 |
D14 |
D29 |
D14 |
D29 |
D14 |
D29 |
|
|
|
||||||||||||||||
| Gl (2.5%) |
2.47a |
3.21bc |
2.81 |
2.58 |
0.53 |
0.57 |
0.80 |
0.69 |
0.07 |
0.09 |
1.45c |
1.08 |
1.69c |
1.42 |
0.88 |
0.79 |
| Lovastatin |
2.36a |
3.00 |
2.44 |
2.81 |
0.50 |
0.60 |
0.59 |
0.71 |
0.10 |
0.09 |
1.40 |
1.29 |
1.50 |
1.43 |
0.95 |
0.91 |
|
Lovastatin was administered at 80 mg/d. Between D1-14, all pigs received a high cholesterol and fat control diet; from D15-29, pigs received either G. lucidum (Gl) extract or lovastatin. The same statistical conclusions were reached if all 10 pigs were compared between D1-14. Pigs were randomly selected to receive either GI or lovastatin before study commencement. Student's, paired, 1-tailed, t-test, was utilized for statistical comparisons. Statistically significant changes (P < 0.05, 1-tailed testing) in cholesterol parameters are indicated as follows: aD1 vs. 14; bD14 vs. 21; cD14 vs. 29. Abbreviations: refer to Table 3. There was a slight trend for 2.5% Gl to reduce LDL/HDL ratio between D14-29 (P < 0.11, 1-tailed testing). | ||||||||||||||||
Berger et al. Lipids in Health and Disease 2004 3:2 doi:10.1186/1476-511X-3-2 |
||||||||||||||||